drug

D-serine 2100 mg daily

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Herzog Hospital
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Investigational (via trials)
SchizophreniaSchizophrenia

Trials

1
D-Serine Monotherapy for Schizophrenia
NCT00215917Phase 1, Phase 2Unknown

KOLs & investigators

1
Pesach Lichtenberg, M.D.KOL score 5

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Herzog Hospital
company
trial
D-Serine Monotherapy for Schizophrenia
PHASE1, PHASE2
trial
indication
Schizophrenia
indication
Schizophrenia
indication
KOL
Pesach Lichtenberg, M.D.
KOL score 5
person